Sound waves open Blood-Brain barrier to attack recurrent brain tumors
NCT ID NCT06329570
First seen Apr 22, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This early study tests whether using focused ultrasound (NaviFUS) to temporarily open the blood-brain barrier can help the drug Avastin work better against recurrent glioblastoma, an aggressive brain cancer. Ten adults whose cancer has returned after standard treatment will receive the combination. The main goal is to check safety, but researchers will also track how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bevacizumab (Avastin) combined with focused ultrasound (NaviFUS system) and microbubbles
What this could lead to
If it works, this could offer a new way to deliver drugs to the brain for recurrent glioblastoma, potentially slowing tumor growth and improving survival.
What could go wrong
This is a very early, small pilot study with only 10 participants. The approach may not work or could cause side effects like bleeding or brain swelling. Success is far from guaranteed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.